Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2430950 | 0.91 | MAPT (0.52) | MAPTLMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL30484131 | 0.85 | KMT2A (0.42) | MAPTLMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL25300687 | 0.85 | KMT2A (0.42) | MAPTLMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL9655014 | 0.85 | AKR1C3 (0.44) | MAPTLMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL9655005 | 0.85 | AKR1C3 (0.44) | MAPTLMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL6646794 | 0.84 | L3MBTL1 (0.47) | MAPTLMNASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL6646756 | 0.84 | KMT2A (0.47) | MAPTLMNAALDH1A1KDM4EMEN1 | |
| SCHEMBL8814509 | 0.84 | ALDH1A1 (0.52) | MAPTLMNASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL4082665 | 0.83 | ALDH1A1 (0.54) | MAPTLMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL7677183 | 0.81 | ALDH1A1 (0.56) | MAPTLMNASMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8019095-B2 | — | — | 1996-02-28 | — | — | JP | claimed |
| EP-0302874-B1 | INDOLOQUINONE COMPOUNDS | SPECKAMP, Willem Nico (NL) | 1992-12-02 | — | — | EP | claimed |
| EP-0302874-A1 | INDOLOQUINONE COMPOUNDS. | SPECKAMP WILLEM NICO (NL) | 1989-02-15 | — | — | EP | claimed |
| WO-1987006227-A2 | INDOLOQUINONE COMPOUNDS | JOUHAR AKBAR JAN (GB) | 1987-10-22 | — | — | WO | claimed |
| US-20080207632-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2008055233-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| US-6596726-B1 | Method of inhibiting epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof inhibit the epidermal growth factor receptor and related receptors and, in particular, their tyrosine kinase enzyme | WARNER LAMBERT COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-5679683-A | USEFUL FOR TREATING CANCER, ARTHRITIS, PSORIASIS, VASCULAR RESTENOSIS AND ANGIOGENESIS | WARNER-LAMBERT COMPANY (US) | 1997-10-21 | — | — | US | disclosed |
| WO-1997023456-A1 | INDOLOQUINONE DERIVATIVES AS BIOREDUCTIVE AGENTS | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1997-07-03 | — | — | WO | disclosed |
| EP-0741711-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995019970-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
| EP-0302874-B1 | INDOLOQUINONE COMPOUNDS | SPECKAMP, Willem Nico (NL) | 1992-12-02 | — | — | EP | disclosed |
| US-5079257-A | Antitumor Agents | SPECTRUM PHARMACEUTICALS, INC. | 1992-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207632-A1 | PROTEIN KINASE INHIBITORS | ERBB3, ERBB2, AXL | MAPT 1472/4885LMNA 2445/4885SMN1; SMN2 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.